Association of Gonadotropin-Releasing Hormone Therapies With Venous Thromboembolic Events in Patients With Prostate Cancer: A National Cohort Study

Chia Nan University of Pharmacy & Science Institutional Repository > 藥理學院 > 保健營養系(所) > 期刊論文 > Item 310902800/34584

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34584

標題:	Association of Gonadotropin-Releasing Hormone Therapies With Venous Thromboembolic Events in Patients With Prostate Cancer: A National Cohort Study
作者:	Hong, Chon-Seng Chen, Yi-Chen Ho, Chung-Han Hsieh, Kun-Lin Chen, Michael Shih, Jhih-Yuan Chiang, Chun-Yen Chen, Zhih-Cherng Chang, Wei-Ting
貢獻者:	Chi Mei Hospital Chi Mei Hospital Southern Taiwan University of Science & Technology Chi Mei Hospital National Cheng Kung University Department of Health and Nutrition, Chia Nan University of Pharmacy & Science Chung Hua University Southern Taiwan University of Science & Technology National Cheng Kung University
關鍵字:	androgen-deprivation therapy risk epidemiology thrombosis agonists disease statins taiwan stroke men
日期:	2022
上傳時間:	2023-12-11 13:59:08 (UTC+8)
出版者:	FRONTIERS MEDIA SA
摘要:	Although androgen deprivation therapy (ADT) has been proposed to be associated with a higher risk of venous thromboembolisms (VTEs), whether gonadotropin-releasing hormones (GnRHs), such as both agonists and antagonists, are also associated with VTEs remain unclear. Using the Taiwan Cancer Registry (TCR) linked with the National Health Insurance Research Database, we identified patients diagnosed with prostate cancer from 2008 to 2015. Patients who received GnRH were 1:1 propensity score matched with non-GnRH users by age and cancer stage at diagnosis and clinical stage. Cox regression analysis was applied to estimate the incidences of VTEs with death as a competing event at the 5-year follow-up. The VTE incidence among GnRH users was 1.13% compared with 0.98% among non-users. After adjusting with potential confounding factors, the risk of VTEs showed borderline statistical significance among GnRH users and non-users. Notably, in the subgroup analysis among patients receiving GnRH therapy, those younger than 70 years old or at an earlier stage (stage I/II) were at a higher risk of VTEs. Different from previous studies, our findings highlighted critical concerns regarding the cardiac safety of GnRH therapies in prostate cancer patients at a relatively younger age or at an earlier stage.
關聯:	FRONTIERS IN CARDIOVASCULAR MEDICINE, v.9
显示于类别:	[保健營養系(所) ] 期刊論文

文件中的档案:

档案	描述	大小	格式	浏览次数
cvm.2022.794310.pdf		504Kb	Adobe PDF	109	检视/开启
index.html		0Kb	HTML	291	检视/开启

在CNU IR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....